AYAs enrolled in trials increased from 9.5 to 14.0 percent after launch of National Clinical Trials Network<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 13, 2022 (HealthDay News) — The proportion of adolescents and young adults (AYAs; aged 15 to 39 years) enrolled in clinical trials increased after launch of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) in 2014, according to a study published online Sept. 12 in Cancer.<\/em><\/p>\n Hari Sankaran, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined accrual data from the NCI Cancer Therapy Evaluation Program (CTEP) cooperative group-led treatment trials to assess enrollment of newly diagnosed AYA patients during 2004 to 2019, especially comparing the periods before and after implementation of the NCI NCTN. A set of 304 trials that met predetermined criteria were included; 151,117 patients were analyzable, including 15,983 AYA patients.<\/p>\n The researchers found that AYA accrual comprised 9.5 and 14.0 percent at pre- and post-NCTN, respectively. The results were similar in sensitivity analyses restricting the pre-NCTN time period to 2010 to 2014 and including non-U.S. resident patients.<\/p>\n “After the launch of the NCTN, the proportion of AYA patients from a total enrollment in NCI CTEP-sponsored clinical trials for newly diagnosed cancers has increased,” the authors write.<\/p>\n